GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $43.55 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $43.55 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Pharma Stock Roundup: FDA Nod to GSK's MMR Jab & SNY's Dupixent Expanded Use
by Kinjel Shah
European Commission approves Roche's (RHHBY) Tecentriq for a new indication. FDA gives the nod to Glaxo's (GSK) new MMR vaccine and Sanofi (SNY) and Regeneron's (REGN) Dupixent for expanded use.
GlaxoSmithKline (GSK) Stock Moves -0.11%: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed the most recent trading day at $44.20, moving -0.11% from the previous trading session.
GSK Gets FDA Nod for Measles, Mumps & Rubella Vaccine, Priorix
by Zacks Equity Research
The FDA approves GSK's Priorix vaccine for active immunization for the prevention of measles, mumps and rubella in individuals aged 12 months and older.
GlaxoSmithKline (GSK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $43.39, marking a +0.81% move from the previous day.
GSK Receives Regulatory Nod for Consumer Healthcare Demerger
by Zacks Equity Research
GSK progresses with the separation of its Consumer Healthcare business from biopharmaceuticals into a separate public company, Haleon, as it gets regulatory approval from the FCA.
GSK to Boost Vaccine Portfolio With Affinivax Acquisition
by Zacks Equity Research
GSK signs an agreement to acquire Affinivax, Inc. for a $2.1 billion upfront payment. The company is looking to boost its vaccine pipeline with this acquisition.
Is Nuveen ESG International Developed Markets Equity ETF (NUDM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for NUDM
Entasis (ETTX) Stock Rises on Buyout Offer From Innoviva
by Zacks Equity Research
Innoviva (INVA) is set to acquire Entasis (ETTX) for $2.20 per share in cash. The transaction is likely to close by third-quarter 2022.
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck, and Glaxo
by Zacks Equity Research
Eli Lilly, Novo Nordisk, Merck, and Glaxo are part of Zacks Industry Outlook article.
Top Analyst Reports for Apple, Berkshire Hathaway, & S&P Global
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Berkshire Hathaway Inc. (BRK.B), and S&P Global Inc. (SPGI).
4 Large Drug Stocks to Watch as the Industry Recovers
by Kinjel Shah
Drug/biotech companies are likely to see significant advances in innovation in 2022. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Glaxo (GSK) are worth retaining in your portfolio.
AstraZeneca (AZN) Inks Deal to Develop COVID-19 Antibodies
by Zacks Equity Research
AstraZeneca (AZN) partners with a U.K.-based biotech company to develop monoclonal antibodies targeting the COVID-causing virus.
Gilead (GILD) HIV Studies Removed From FDA's Clinical Hold
by Zacks Equity Research
Gilead (GILD) studies evaluating injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP) removed from hold.
Gilead (GILD) Q1 Earnings Beat on Solid COVID Treatment Sales
by Zacks Equity Research
Gilead (GILD) beats on earnings and revenues in the first quarter on strong Veklury sales. HIV business maintains momentum on Biktarvy.
Glaxo's (GSK) Q1 Earnings Top, Xevudy Adds $1.7B in Sales
by Zacks Equity Research
Glaxo's (GSK) revenues benefit from the strong growth in sales across all categories along with additional sales from its COVID-19 antibody drug, Xevudy.
Drug/Biotech Stocks' Apr 27 Q1 Earnings Roster: GSK, AMGN & More
by Kanishka Das
Let us take a look at four drug/biotech companies, namely, GSK, AMGN, ALKS and BMRN, which are due to release their quarterly results on Apr 27.
Glaxo (GSK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Glaxo's (GSK) COVID-19 solutions, newer respiratory and HIV drugs are likely to have driven first-quarter sales. The performance of vaccines during Q1 remains to be seen.
Pharma Stock Roundup: J&J's Mixed Q1 Results, FDA Updates for GSK and AZN
by Kinjel Shah
J&J (JNJ) reports mixed first-quarter results and cuts full-year outlook. AstraZeneca (AZN) and Glaxo (GSK) provide FDA updates.
GlaxoSmithKline (GSK) Stock Moves -0.33%: What You Should Know
by Zacks Equity Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $45.69, marking a -0.33% move from the previous day.
Glaxo's (GSK) NDA for Daprodustat Gets Accepted by the FDA
by Zacks Equity Research
Glaxo's (GSK) NDA for daprodustat is based on data from the ASCEND phase III program comprising five studies. All the studies meet their primary efficacy and safety endpoints.
GlaxoSmithKline (GSK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $45.89, marking a -0.67% move from the previous day.
Regeneron (REGN) REGEN-COV BLA Review Extended by 3 Months
by Zacks Equity Research
Regeneron (REGN) biologics license application for antibody cocktail REGEN-COV (casirivimab and imdevimab) gets a three-month FDA extension.
Merck's (MRK) Pneumococcal Jab Gets FDA's Breakthrough Tag
by Zacks Equity Research
The FDA grants Breakthrough Therapy designation to Merck's (MRK) vaccine candidate, V116, for preventing invasive pneumococcal disease and pneumococcal pneumonia in adults.
Biotech Stock Roundup: SRRA Surges on GSK Buyout, HALO Offers Update & More
by Zacks Equity Research
Acquisition news from GlaxoSmithKline (GSK) and HALO are a few key highlights from the biotech sector during the past week.
Halozyme (HALO) to Acquire Antares for Auto Injector Platform
by Zacks Equity Research
Halozyme (HALO) is set to acquire Antares for $960 million by June. The acquisition will add Antares' auto injector platform to Halozyme's portfolio and complement its promising ENHANZE technology.